Flolipid is a drug owned by Salerno Pharmaceuticals. It is protected by 2 US drug patents filed from 2017 to 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 23, 2030. Details of Flolipid's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9597289 | Liquid oral simvastatin compositions |
Feb, 2030
(4 years from now) | Active |
| US10300041 | Liquid oral simvastatin compositions |
Apr, 2027
(1 year, 11 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Flolipid's patents.
Latest Legal Activities on Flolipid's Patents
Given below is the list of recent legal activities going on the following patents of Flolipid.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Oct, 2022 | US10300041 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Sep, 2020 | US9597289 |
| Recordation of Patent Grant Mailed Critical | 28 May, 2019 | US10300041 |
| Patent Issue Date Used in PTA Calculation Critical | 28 May, 2019 | US10300041 |
| Email Notification Critical | 09 May, 2019 | US10300041 |
| Issue Notification Mailed Critical | 08 May, 2019 | US10300041 |
| Dispatch to FDC | 09 Apr, 2019 | US10300041 |
| Application Is Considered Ready for Issue Critical | 08 Apr, 2019 | US10300041 |
| Issue Fee Payment Verified Critical | 05 Apr, 2019 | US10300041 |
| Issue Fee Payment Received Critical | 05 Apr, 2019 | US10300041 |
US patents provide insights into the exclusivity only within the United States, but Flolipid is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Flolipid's family patents as well as insights into ongoing legal events on those patents.
Flolipid's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Flolipid's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 23, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Flolipid Generic API suppliers:
Simvastatin is the generic name for the brand Flolipid. 16 different companies have already filed for the generic of Flolipid, with Zydus Pharms Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Flolipid's generic
Alternative Brands for Flolipid
There are several other brand drugs using the same active ingredient (Simvastatin) as Flolipid. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Simvastatin, Flolipid's active ingredient. Check the complete list of approved generic manufacturers for Flolipid
About Flolipid
Flolipid is a drug owned by Salerno Pharmaceuticals. Flolipid uses Simvastatin as an active ingredient. Flolipid was launched by Salerno Pharms in 2016.
Approval Date:
Flolipid was approved by FDA for market use on 21 April, 2016.
Active Ingredient:
Flolipid uses Simvastatin as the active ingredient. Check out other Drugs and Companies using Simvastatin ingredient
Dosage:
Flolipid is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG/5ML | SUSPENSION | Prescription | ORAL |
| 40MG/5ML | SUSPENSION | Prescription | ORAL |